<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03606876</url>
  </required_header>
  <id_info>
    <org_study_id>BAT-1806-001-CR</org_study_id>
    <nct_id>NCT03606876</nct_id>
  </id_info>
  <brief_title>Comparative Study to Evaluate the Pharmacokinetics of BAT1806 vs Actemra® in Healthy Subjects</brief_title>
  <official_title>A Randomized, Double-blinded, Single-dose, 3-arm Parallel, Comparative Study to Evaluate the Pharmacokinetics and Safety of BAT1806 Injection vs Actemra® in Healthy Chinese Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bio-Thera Solutions</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bio-Thera Solutions</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is a randomized, double-blinded, single-dose, 3-arm parallel, comparative study to&#xD;
      evaluate the pharmacokinetics, safety and immunogenicity of BAT1806 Injection vs Actemra®&#xD;
      (EU-licensed and US-licensed) in healthy Chinese male subjects. A total of 138 subjects are&#xD;
      planned to be included and randomized at a ratio of 1:1:1 to receive single intravenous drip&#xD;
      of 4 mg/kg BAT1806 Injection or Actemra® (EU-licensed and US-licensed).&#xD;
&#xD;
      The study has a screening period of 7 days. PK blood samples will be collected from subjects&#xD;
      to determine the serum concentration of tocilizumab, thus to evaluate the change and&#xD;
      similarity of the pharmacokinetics of the three study drugs.&#xD;
&#xD;
      The investigator will perform safety evaluation for vital signs, physical examinations,&#xD;
      injection site reaction, ECG, clinical laboratory tests and adverse events throughout the&#xD;
      study. Immunogenicity evaluation (ADA, ADA titration and nAb) will also be evaluated.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 13, 2018</start_date>
  <completion_date type="Actual">July 17, 2019</completion_date>
  <primary_completion_date type="Actual">July 17, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics Endpoint</measure>
    <time_frame>0-2months</time_frame>
    <description>AUC0-inf</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics Endpoint</measure>
    <time_frame>0-2months</time_frame>
    <description>AUC0-t</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics Endpoint</measure>
    <time_frame>0-2months</time_frame>
    <description>Cmax</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">138</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>BAT1806 injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BAT1806 injection: 4 mg/kg, intravenous infusion over 60 min</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Actemra(EU-licensed)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Actemra(EU-licensed): 4 mg/kg, intravenous infusion over 60 min</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Actemra(US-licensed)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Actemra(US-licensed): 4 mg/kg, intravenous infusion over 60 min</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BAT1806 injection</intervention_name>
    <description>Each subject will receive single intravenous drip of 4 mg/kg BAT1806 Injection or Actemra® (EU-licensed and US-licensed).</description>
    <arm_group_label>Actemra(EU-licensed)</arm_group_label>
    <arm_group_label>Actemra(US-licensed)</arm_group_label>
    <arm_group_label>BAT1806 injection</arm_group_label>
    <other_name>Actemra(EU-licensed)</other_name>
    <other_name>Actemra(US-licensed)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed the Inform Consent Form and fully understood the trial conduction, procedure&#xD;
             and potential adverse reactions before entering the trial;&#xD;
&#xD;
          -  Willing and able to follow the visits, treatments specified in this study;&#xD;
&#xD;
          -  Subjects (including their partners) who are willing to refrain from pregnancy, sperm&#xD;
             donation and take effective contraceptive method in the future 6 months (i.e. 6 months&#xD;
             after study medication), see Appendix 4 for specific contraceptive methods;&#xD;
&#xD;
          -  Healthy male subjects at age of 18-55 years (inclusive for both);&#xD;
&#xD;
          -  BMI between 18-28 kg/m2 (inclusive for both) and body weight between 55-85 kg&#xD;
             (inclusive for both);&#xD;
&#xD;
          -  Normal physical examinations results or abnormality without clinical significance.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Daily smoking amount of &gt;5 cigarettes within 3 months prior to the trial;&#xD;
&#xD;
          -  Any current or history of severe allergic reaction to foods or drugs and History of&#xD;
             allergy to tocilizumab or severe allergic or anaphylactic reactions to human,&#xD;
             humanized, or murine monoclonal antibodies.&#xD;
&#xD;
          -  Having a history of alcoholism (14 units of alcohol per week: 1 unit= 285 mL beer, or&#xD;
             25 mL spirit, or 125 mL wine);&#xD;
&#xD;
          -  Having donated blood or loss of massive blood (&gt; 450 mL) within 3 months prior to&#xD;
             screening, or planning to donate blood or to receive surgery during the study;&#xD;
&#xD;
          -  Prior use of prescription medication, over-the-counter drugs, any vitamin products or&#xD;
             herbs within 28 days before screening;&#xD;
&#xD;
          -  Having significant changes in diet and exercise habits within 2 weeks before screening&#xD;
             or from screening to dose;&#xD;
&#xD;
          -  Having any diseases that increase the risk of bleeding, such as hemorrhoids with&#xD;
             bleeding symptoms, acute gastritis or gastric and duodenal ulcers;&#xD;
&#xD;
          -  Color Doppler echocardiography abnormalities with clinical significance;&#xD;
&#xD;
          -  Having clinically significant laboratory abnormalities or other clinically indicated&#xD;
             diseases (including but not limited to gastrointestinal, renal, liver, neurological,&#xD;
             hematological, endocrine, tumor, lung, immune, mental or cardiovascular diseases);&#xD;
&#xD;
          -  Ineligible subjects based on investigator's judgement.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>yanhua ding</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Hospital of Jilin University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The First Bethune Hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>July 12, 2018</study_first_submitted>
  <study_first_submitted_qc>July 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 31, 2018</study_first_posted>
  <last_update_submitted>November 16, 2021</last_update_submitted>
  <last_update_submitted_qc>November 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Only one site study</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

